ASCO GU 2025 | Dr. Thomas Powles: EV+P Regimen Redefines Platinum-Based Chemotherapy, Setting a New First-Line Standard for Urothelial Cancer

ASCO GU 2025 | Dr. Thomas Powles: EV+P Regimen Redefines Platinum-Based Chemotherapy, Setting a New First-Line Standard for Urothelial Cancer

2025.03.10
Urothelial carcinoma (UC) is the second most common malignancy of the urinary system, characterized by poor prognosis and low five-year survival rates. For decades, platinum-based chemotherapy has remained the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). However, limited clinical benefit and poor tolerability have left many unmet treatment needs.
Dr. Neeraj Agarwal: Talazoparib Plus Enzalutamide Extends First-Line OS to Nearly Four Years, Pioneering a New Era in Precision Treatment for mCRPC

Dr. Neeraj Agarwal: Talazoparib Plus Enzalutamide Extends First-Line OS to Nearly Four Years, Pioneering a New Era in Precision Treatment for mCRPC

2025.03.10
The 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13 to 15 in San Francisco, California, bringing together leading experts and researchers in the field of genitourinary oncology. Among the key highlights was the final overall survival (OS) data from the TALAPRO-2 trial, presented by Dr. Neeraj Agarwal from the Huntsman Cancer Institute (HCI), University of Utah. The study drew widespread attention as it not only addressed a critical gap in first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) using a PARP inhibitor in combination with next-generation hormonal therapy (NHT) but also reinforced the growing role of precision medicine in prostate cancer treatment.
ASCO GI 2025 | Dr. Scott Kopetz: EC + FOLFOX Regimen Significantly Improves Response Rates in mCRC, Delivering Rapid and Durable Efficacy

ASCO GI 2025 | Dr. Scott Kopetz: EC + FOLFOX Regimen Significantly Improves Response Rates in mCRC, Delivering Rapid and Durable Efficacy

2025.03.10
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25, showcasing the latest advances in gastrointestinal cancer research and treatment strategies. One of the most notable studies was the BREAKWATER trial (Abstract #16), which focused on BRAF V600E-mutant metastatic colorectal cancer (mCRC). This study demonstrated a significant improvement in response rates and durable efficacy, positioning EC + FOLFOX as a promising first-line treatment option for this high-risk patient group. The findings also provide further evidence for the role of precision medicine in mCRC, reinforcing the need to integrate targeted therapy into earlier treatment settings.
Annual Review | Dr. Jianyong Li: Advances in CLL/SLL Treatment in 2024 – BTK Inhibitors Leading the “Chemo-Free” Era

Annual Review | Dr. Jianyong Li: Advances in CLL/SLL Treatment in 2024 – BTK Inhibitors Leading the “Chemo-Free” Era

2025.03.06
As we bid farewell to the past year and step into a new chapter, the field of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has seen remarkable progress. Targeted therapies, particularly Bruton's tyrosine kinase (BTK) inhibitors, have not only significantly improved patient survival outcomes but have also driven a paradigm shift away from traditional immunochemotherapy towards a "chemo-free" treatment model.